Logo-ipp
Submitted: 06 Aug 2019
Accepted: 10 Dec 2019
ePublished: 25 Dec 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2020;6(1): e07.
doi: 10.15171/ipp.2020.07
  Abstract View: 533
  PDF Download: 255

Original Article

Prognostic significance evaluation of B-cell lymphoma 2 (BCL2) and Ki-67 expression in diffuse large B-cell lymphoma patients

Hossein Rahimi 1 ORCID logo, Zahra Rezaei Borojerdi 1 * ORCID logo, Sajad Ataei Azimi 1 * ORCID logo, Elnaz Rashidian 2 ORCID logo, Amirhossein Jafarian 3 ORCID logo

1 Devision of Hematology Oncology, Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Division of Surgery, Department of Surgery, Mashhad University of Medical Sciences, Mashhad, Iran
3 Molecular Pathology Research Center, Department of Pathology Faculty, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphatic neoplasm, accounting for about 30–40% of non-Hodgkin’s lymphoma cases. Objectives: DLBCL is a progressive disease with clinical, genetic and molecular heterogeneity. The prognostic value of B-cell lymphoma 2 (BCL2) and Ki-67 in DLBCL patients has been controversial.

Patients and Methods: In this study, we investigated the correlation of BCL2 and Ki-67 expression with clinical features such as age, gender, B symptoms and lactate dehydrogenase (LDH) levels, subtypes of DLBCL, its staging and prognosis in 36 cases of DLBCL. The expression of BCL2 and Ki-67 was measured by immunohistochemistry.

Results: There was no significant correlation between BCL2 expression and staging (P=0.082), however Ki-67 expression had a significant correlation with staging (P=0.002). There was no statistically significant correlation between BCL2 and Ki-67 with prognosis of the disease. We found a significant correlation between the germinal center B-cell (GCB) and non- GCB subtypes with BCL2 expression (P=0.024), since patients with non- GCB subtype had a higher BCL2 expression. Our study also demonstrated a significant relationship between BCL2 and Ki-67 expression, therefore, with the increase of the expression of a marker, another increases (P=0.045).

Conclusion: BCL2 and Ki-67 expressions were not associated with prognosis. Overexpression of Ki-67 was associated with higher clinical stages. BCL2 expression is higher in non-GCB subtype of DLBCL. Therefore, our study shows that the subsequent studies of BCL2 and other biomarkers in the DLBCL should be based on the DLBCL subtypes. 

Keywords: Diffuse Large B Cell Lymphoma, Bcl2, Ki-67, immunohistochemistry
Citation: Rahimi H, Rezaei Borojerdi Z, Ataei Azimi S, Rashidian E, Jafarian A. Prognostic significance evaluation of B-cell lymphoma 2 (BCL2) and Ki-67 expression in diffuse large B-cell lymphoma patients. Immunopathol Persa. 2020;6(1):e07. DOI:10.15171/ ipp.2020.07.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 533

Your browser does not support the canvas element.


PDF Download: 255

Your browser does not support the canvas element.